@ETPharma

A Single Portal for All-Inclusive Pharma News Coverage. A Part of @ETHealthWorld

Joined May 2023
  • Tweets4.6K
  • Following6
  • Followers296
2.8KMedia
DCGI pulls cosmetic FatX marketing approval over dubious fat-dissolving claims #FatX I #Fat_dissolver I #Cosmetic I #Import_registration I #India I #Misleading_claims I @CDSCO_INDIA_INF Read more: pharma.economictimes.indiati…

DCGI pulls cosmetic FatX marketing approval over dubious fat-dissolving claims

India's drug regulator DCGI cancels the import registration of FatX, a cosmetic product marketed with unauthorized fat-dissolving claims, highlighting the distinction between drugs and cosmetics.

pharma.economictimes.indiatimes.com
7
Cipla targets first wave launch for Keytruda biosimilar; sees 5% monthly gain in Yurpeak sales #Keytruda I #Biosimilar I #US_Launch I #Q2_earnings I #Tirzepatide I #Yurpeak I @Cipla_Global Read more: pharma.economictimes.indiati…

Cipla targets first wave launch for Keytruda biosimilar; sees 5% monthly gain in Yurpeak sales

Cipla targets a first wave launch of its Keytruda biosimilar QL2107 in the US after patent expiry in 2029, with expectations of capturing significant market share. Additionally, Yurpeak sales are...

pharma.economictimes.indiatimes.com
13
Centre sounds alarm over fake liver drug batch after WHO alert #Public_alert I #Counterfeit I #Fake_copy I #India I #defibrotide I #rare_disease I @CDSCO_INDIA_INF I @WHO I @JazzPharma I @MoHFW_INDIA Read more: pharma.economictimes.indiati…

Centre sounds alarm over fake liver drug batch after WHO alert

The CDSCO has raised a public alert regarding a counterfeit batch of the liver medication Defitelio, prompting patients to procure medications only from authorized sources after concerns raised by...

pharma.economictimes.indiatimes.com
10
Cipla-Sino bispecific ADC cuts Cancer progression by 71% in late-stage China trial #Cancer I #ADC I #Bispecific I #Phase3_results I @myESMO I @Cipla_Global I #SBPGroup Read more: pharma.economictimes.indiati…

Cipla-Sino bispecific ADC cuts Cancer progression by 71% in late-stage China trial

Cipla's bispecific ADC rolditamig deruxtecan demonstrates a remarkable 71% reduction in disease progression for late-stage breast cancer patients in a Phase 3 trial, presenting a significant advanc...

pharma.economictimes.indiatimes.com
11
Why entire system working to help pharmaceutical manufacturers, asks SC #Medicine I #Mark_ups I #Ceiling I #DPCO I #SC I #Drug_manufacturers I #India Read more: pharma.economictimes.indiati…

Why entire system working to help pharmaceutical manufacturers, asks SC

The Supreme Court of India is questioning why the government is aiding pharmaceutical manufacturers despite significant price differences between MRP and retail prices of medicines, as it reviews the...

pharma.economictimes.indiatimes.com
7
Cipla misses Q2 estimates as net profit tumbles 35% to ₹878 cr #Pharma I #Q2 I #FY27 I #Earnings I #US_biz I @Cipla_Global Read more: pharma.economictimes.indiati…

Cipla misses Q2 estimates as net profit tumbles 35% to ₹878 cr

Cipla's Q2 earnings report reveals a significant 35% decline in net profit to ₹878 crore, missing analyst estimates. Revenue dropped 2.4% to ₹7,403 crore, with North American sales suffering a 19%...

pharma.economictimes.indiatimes.com
12
US judge refuses to block Eli Lilly weight-loss drug ads, rules against Novo Nordisk #Weightloss_drugs I #Advertisement I #Promotion I #US I #Ruling I @EliLillyandCo I @novonordisk Read more: pharma.economictimes.indiati…

US judge refuses to block Eli Lilly weight-loss drug ads, rules against Novo Nordisk

A US judge rules in favor of Eli Lilly, allowing its weight-loss drug advertisements to continue, despite Novo Nordisk's claims of false advertising. The decision affects a multi-billion dollar...

pharma.economictimes.indiatimes.com
9
GSK, Hansoh's bone cancer drug delays disease progression in late-stage China study #Bone_cancer I #drug I #Clinical_trial I #Phase3 I #China I @myESMO I @GSK Read more: pharma.economictimes.indiati…

GSK, Hansoh's bone cancer drug delays disease progression in late-stage China study

The experimental drug ris-rez, developed by GSK and Hansoh Pharmaceutical, significantly delays disease progression in osteosarcoma, offering hope for better treatment options in oncology.

pharma.economictimes.indiatimes.com
8
Bala Subramanian, Bugworks Research India Pvt. Ltd., joins the ET Pharma BioTech Leadership Symposium 2026 to share perspectives on advancing biotech innovation and addressing some of healthcare’s most urgent challenges. Register Now: pharma.economictimes.indiati… #ETBioTech
24
Biocon inks settlement with J&J arm to launch Stelara biosimilar in nine more markets #Stelara I #Biosimilar I #License I #Launch I #Agreement I @Bioconlimited I @JNJNews Read more: pharma.economictimes.indiati…

Biocon inks settlement with J&J arm to launch Stelara biosimilar in nine more markets

Biocon has secured a license to introduce its Stelara biosimilar in nine additional countries, expanding treatment access for autoimmune diseases amid increasing biosimilar competition.

pharma.economictimes.indiatimes.com
53
Roche KRAS contender outclass rivals in survival, reducing death risk in late-stage cancer trial #Lung_Cancer I #KRAS_Mutation I #Divarasib I #Head_to_Head I #Death_risk I #Survival I @myESMO I @Roche I @bmsnews I @Amgen Read more: pharma.economictimes.indiati…

Roche KRAS contender outclass rivals in survival, reducing death risk in late-stage cancer trial

Roche's investigational cancer drug divarasib significantly lowers the risk of death for patients with KRAS G12C-mutated non-small cell lung cancer, outperforming current treatments in a recent phase...

pharma.economictimes.indiatimes.com
39
AstraZeneca's stomach cancer drug extends overall survival, late-stage trial data finds #Stomach_cancer I #Drug I #Sone_Ve I #ADC I @myESMO I @AstraZeneca Read more: pharma.economictimes.indiati…

AstraZeneca's stomach cancer drug extends overall survival, late-stage trial data finds

AstraZeneca's late-stage trial data reveals significant improvements in overall survival for advanced stomach cancer patients using the drug sone-ve, outperforming chemotherapy and raising potential...

pharma.economictimes.indiatimes.com
32
Sun Pharma’s Unolxcyt shows sustained cancer control in two year follow-up #Unloxcyt I #Skin_cancer I #ORR I #CR I #Squamous_cell I #Two_years I #Follow_up I @myESMO I @SunPharma_Live Read more: pharma.economictimes.indiati…

Sun Pharma’s Unolxcyt shows lasting cancer control in long-term follow-up

Sun Pharma's Unolxcyt shows a significant objective response rate and durable cancer control for patients with advanced skin cancer in a two-year follow-up study presented at the ESMO congress.

pharma.economictimes.indiatimes.com
1
84
Esco Lifesciences Group joins the ET Pharma BioTech Leadership Symposium 2026 as the Co-Presenting Partner, supporting conversations around the next phase of India’s biotech growth 11 December 2026 | Le Meridien Hyderabad Register Now: pharma.economictimes.indiati… #ETBioTech
1
29
Johnson & Johnson's prostate cancer drug shrinks tumors in early-stage trial #Prostate_cancer I #Tumor I #ORR I #Drug I #PSA_reduction I @JNJNews I @myESMO Read more: pharma.economictimes.indiati…

Johnson & Johnson's prostate cancer drug shrinks tumors in early-stage trial

Johnson & Johnson's experimental prostate cancer drug, JNJ-6143, has shown significant tumor shrinkage and reduced PSA levels in an early-stage trial, offering hope for advanced prostate cancer...

pharma.economictimes.indiatimes.com
1
57
Bristol Myers discloses patient death in early-stage cell therapy study #Cell_therpay I #CAR_T I #Death I #Trial I @esModayEstilo I @bmsnews Read more: pharma.economictimes.indiati…

Bristol Myers discloses patient death in early-stage cell therapy study

Bristol Myers Squibb reveals a patient death during an early-stage trial of its experimental CAR-T cell therapy for multiple sclerosis, following a voluntary pause in studies to review safety data....

pharma.economictimes.indiatimes.com
19
Amgen drug combined with immunotherapy extends survival in lung cancer trial #Cancer I #Combo I #Imdelltra I #Imfinzi I #Trial I @myESMO I @Amgen Read more: pharma.economictimes.indiati…

Amgen drug combined with immunotherapy extends survival in lung cancer trial

A groundbreaking study reveals that Amgen's Imdelltra, when combined with AstraZeneca's immunotherapy Imfinzi, significantly improves survival rates for patients with extensive-stage small cell lung...

pharma.economictimes.indiatimes.com
27
AbbVie's skin disease drug reduces lesions in trial, company eyes weight-loss combination #Derma_drug I #Trial I #Results I #Lumps I #ABBV_295 I @abbvie Read more: pharma.economictimes.indiati…

AbbVie's skin disease drug reduces lesions in trial, company eyes weight-loss combination

AbbVie announced promising results for its experimental drug lutikizumab in reducing skin lesions from hidradenitis suppurativa while planning a combination trial with its weight-loss drug ABBV-295.

pharma.economictimes.indiatimes.com
24
Merck/Moderna cancer vaccine cuts risk of death or recurrence from melanoma by over 40% #Skin_cancer I #Melanoma I #Vaccine I #mRNA I #Relapse I @moderna_tx I @Merck I @myESMO Read more: pharma.economictimes.indiati…

Merck/Moderna cancer vaccine cuts risk of death or recurrence from melanoma by over 40%

A revolutionary mRNA cancer vaccine developed by Moderna and Merck, combined with immunotherapy, shows a 42% reduction in death and recurrence rates for melanoma in a large clinical trial, marking a...

pharma.economictimes.indiatimes.com
28
Novartis presents weaker-than-expected relapse data for multiple sclerosis drug remibrutinib #Multiple_Sclerosis I #Drug I #Trial I #Data I #M_Toronto I @Novartis Read more: pharma.economictimes.indiati…

Novartis presents weaker-than-expected relapse data for multiple sclerosis drug remibrutinib

Novartis presents disappointing data for remibrutinib, its oral multiple sclerosis drug, showing lower than anticipated relapse reduction compared to Roche's fenebrutinib. Analysts concerned over the...

pharma.economictimes.indiatimes.com
41
Load more